Detalles de la búsqueda
1.
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
Int J Cancer
; 153(1): 133-140, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36752579
2.
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Int J Cancer
; 153(8): 1520-1528, 2023 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391938
3.
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
Int J Cancer
; 151(3): 473-480, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35429341
4.
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.
Future Oncol
; 14(24): 2493-2505, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29969285
5.
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
JAMA Netw Open
; 7(4): e245635, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592721
6.
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.
Mol Clin Oncol
; 18(2): 9, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36761386
7.
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
Cancers (Basel)
; 15(7)2023 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046778
8.
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Clin Cancer Res
; 29(12): 2299-2309, 2023 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37040395
9.
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 9(7): 966-970, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37200022
10.
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.
Front Oncol
; 12: 813462, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35419293
11.
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
Clin Colorectal Cancer
; 21(2): 141-148, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101346
12.
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941.
Cancers (Basel)
; 14(16)2022 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36011056
13.
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study.
Cancers (Basel)
; 14(20)2022 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291765
14.
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Ther Adv Med Oncol
; 14: 17588359221096878, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35547096
15.
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
J Exp Clin Cancer Res
; 41(1): 109, 2022 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35346313
16.
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Target Oncol
; 17(6): 635-642, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239883
17.
Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event.
Life (Basel)
; 11(9)2021 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34575102
18.
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Clin Colorectal Cancer
; 20(3): 227-235, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34226142
19.
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy.
Cancers (Basel)
; 13(22)2021 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34830870
20.
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer.
Cancers (Basel)
; 13(8)2021 04 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33920531